title: Targeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumab.
abstract: In this study, we prepared iron oxide nanoparticle and doxorubicin-loaded multifunctional nano-carrier (IONP/DOX-MFNC), capable of simultaneous cancer targeting via a herceptin monoclonal antibody, controlled anticancer drug delivery, as well as imaging modalities of magnetic resonance imaging (MRI) and near-infrared fluorescence (NIRF) imaging. IONP and DOX were efficiently loaded into the nano-carrier, and a desirable pH-responsive release of DOX was achieved by MFNC. The nano-carrier showed much higher cellular uptake and stronger cytotoxicity to HER2 overexpressed SK-BR-3 (human breast cancer cells) than MCF-7, a negative control cell, suggesting specific cancer targeting via HER2 receptor. In an in vivo tumor xenograft model, IONP/DOX-MFNC showed higher tumor uptake and significantly enhanced tumor regression than the nano-carrier without the antibody. Thus, DOX-loaded, multi-functional nano-carrier with HER2 antibody was effective for both imaging and therapy, showing the potential for early stage cancer diagnosis and simultaneous therapy.
  
  
  BACKGROUND
  In this study, efficacy -both for imaging and treatment - was demonstrated on a doxorubicin and iron oxide nanoparticle loaded multifunctional nano-carrier with HER2 antibody to show the potential for early stage cancer diagnosis and simultaneous therapy.
authors.affiliation: School of Materials Science and Engineering, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.
authors.forename: Won Il
authors.initials: WI
authors.lastname: Choi
authors.affiliation: School of Materials Science and Engineering, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.
authors.forename: Jong Hyun
authors.initials: JH
authors.lastname: Lee
authors.affiliation: School of Materials Science and Engineering, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.
authors.forename: Ja-Young
authors.initials: JY
authors.lastname: Kim
authors.affiliation: Department of Radiology, Chonnam National University Medical School, Gwangju, Republic of Korea.
authors.forename: Seon U
authors.initials: SU
authors.lastname: Heo
authors.affiliation: Department of Radiology, Chonnam National University Medical School, Gwangju, Republic of Korea.
authors.forename: Yong Yeon
authors.initials: YY
authors.lastname: Jeong
authors.affiliation: School of Materials Science and Engineering, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.
authors.forename: Young Ha
authors.initials: YH
authors.lastname: Kim
authors.affiliation: School of Materials Science and Engineering, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea. Electronic address: gytae@gist.ac.kr.
authors.forename: Giyoong
authors.initials: G
authors.lastname: Tae
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000737:chemistry; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000737:chemistry; D000970:Antineoplastic Agents; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003287:Contrast Media; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry; D016503:Drug Delivery Systems; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D061986:MCF-7 Cells; D008279:Magnetic Resonance Imaging; D053768:Metal Nanoparticles / Q000008:administration & dosage / Q000737:chemistry; D051379:Mice; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology / Q000627:therapeutic use; D000068878:Trastuzumab; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003287:Contrast Media; D004317:Doxorubicin; D005290:Ferric Compounds; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C000499:ferric oxide; C508053:ERBB2 protein, human
keywords: Active targeting; Doxorubicin; Herceptin; NIR imaging; Pluronic